Private and public biotech firms pulled in a wave of capital in early January ahead of the JP Morgan conference. Endpoints News tallied roughly $4.9 billion in financings across private and public companies, while BioCentury reported private biotechs raised roughly $2 billion in a concentrated week. The fundraising included mega-rounds and multiple mid-size raises, reflecting concentrated investor activity and dealmaking ahead of industry meetings.